Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin(The University of Texas MD Anderson Cancer Center), Fuliang Chu(The University of Texas MD Anderson Cancer Center), Min Zhang(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Nathan Fowler(The University of Texas MD Anderson Cancer Center), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center), Michelle A. Fanale(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Lei Feng(The University of Texas MD Anderson Cancer Center), Veerabhadran Baladandayuthapani(The University of Texas MD Anderson Cancer Center), Zhiqiang Wang(The University of Texas MD Anderson Cancer Center), Wencai Ma(The University of Texas MD Anderson Cancer Center), Yan-Li Gao(The University of Texas MD Anderson Cancer Center), Michael B. Wallace(The University of Texas MD Anderson Cancer Center), Luis M. Vence(The University of Texas MD Anderson Cancer Center), Laszlo Radvanyi(The University of Texas MD Anderson Cancer Center), Tariq Muzzafar(The University of Texas MD Anderson Cancer Center), Rinat Rotem‐Yehudar(CureTech (Israel)), R. Eric Davis(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center)
Cited by 530
Abstract
Related Papers
No related papers found
Powered by citation graph analysis